Revolution Ready To Market Rasonque As Pancreatic Cancer Standard Of Care
Revolution Medicine won US FDA approval for its RAS(ON) inhibitor Rasonque (daraxonrasib) in second-line metastatic pancreatic adenocarcinoma, making it the first targeted therapy for PDAC.
Scrip - August 26, 2026

Lilly Study Finds Zepbound Offsets Costs Under Medicare Bridge Program
The drugmaker published a study showing that lower emergency room visits and hospitalizations offset $195 per month cost for the drug under the Medicare GLP-1 Bridge.
Scrip - August 26, 2026

Biohaven Monetizes Epilepsy Candidate To Address Financial Woes In Pact With SK
Deal snapshot: South Korea’s SK Biopharmaceuticals will add opakalim to its epilepsy portfolio, paying Biohaven $350m at closing for the Phase II/III ion channel modulator.
Scrip - August 26, 2026

Spyre Misses In RA But Autoimmune Combos Could Pay Off
The rheumatoid arthritis failure for its TL1A antibody was not unexpected and analysts see the US biotech’s attempt to develop two-drug combinations in ulcerative colitis as its best chance in a crowded field.
Scrip - August 26, 2026

Immatics Tops Up Coffers As Cancer Drugs Advance
The Germany-based biotech has decided to bolster the balance sheet as it prepares for key readouts on its cell therapy and bispecific candidates.
Scrip - August 26, 2026

Jazz Forecasts Up To $5bn In Ziihera Peak Sales After Gastroesophageal Cancer Approval
The focus will now shift to launch uptake, competitive displacement and whether the drug can establish itself across a broader HER2 franchise.
Scrip - August 26, 2026

New Standard Of Care As Ivonescimab Bests Imfinzi In 1L Biliary Tract Cancer?
Akeso’s ivonescimab plus chemo beats Imfinzi plus chemo in overall survival terms in head-to-head Phase III trial in untreated biliary tract cancer.
Scrip - August 26, 2026

Cyberattack Makes Boston Scientific The Latest Medtech Target As Orders Are Disrupted
Medical device giant hit by cybersecurity incident on Aug. 25, triggering network outages, shipment disruptions and work-from-home orders for thousands of employees. The scope, data impact and financial hit remain unknown; shares fell about 4%.
Medtech Insight - August 27, 2026

Beauty Supply Chains Face Fresh Threat As US-Canada Tariff War Escalates
The Personal Care Products Council says trade tensions and new tariffs between the US and Canada threaten to disrupt North American supply chains for cosmetics and personal care products.
HBW Insight - August 26, 2026

Poison Control Center Data Support Regulatory Distinction Between Kratom Leaf And Synthetics
“This evidence is essential to promoting safe kratom use, identifying high-risk combinations of substances, and guiding public health action to prevent future health effects in this rapidly evolving drug landscape,” say University of Virginia Health researchers.
HBW Insight - August 26, 2026

Single-Ingredient Acetaminophen Most Common Drug In Poison Center Reports Of Liver Damage
Total of 33,085 single-ingredient acetaminophen drugs accounted for 32.6% of the 10 medications or other substances most frequently linked to liver injuries and reported to poison centers from 2000 to 2024.
HBW Insight - August 26, 2026

Don’t Sleep On It: Melatonin Ban In Hungary Is Wake Up Call For Supplements Industry
Hungary's ban on melatonin in supplements has put the ingredient's EU regulatory status back under the microscope. Experts warn the decision could encourage other member states to review their own positions and may reactivate an on-hold EU-wide Article 8 safety review.
HBW Insight - August 26, 2026

Zydus Gets CGT Exclusivity On Scurvy Treatment
Zydus Lifesciences has announced US Food and Drug Administration approval for its generic ascorbic acid for injection, accompanied by 180 days of CGT exclusivity.
Generics Bulletin - August 26, 2026

Biocon And Sandoz Broaden Japanese Biosimilars Alliance With Pegfilgrastim Nod
Biocon has received a Japanese approval for its pegfilgrastim biosimilar rival to Amgen’s Neulasta, which will be marketed through an alliance with Sandoz.
Generics Bulletin - August 26, 2026

Alvotech’s Reykjavik Recovery Sets Stage For Pivotal Quarter
Alvotech is looking to a pivotal fourth quarter of FDA decisions, potential legal developments and stronger supply as it works to support 2026 guidance and prepare multiple US biosimilar launches.
Generics Bulletin - August 26, 2026

What Is A TechBio, Exactly? France Is Betting The Definition Matters
The France TechBio Commission was born partly from a meeting at the Élysée Palace and a simple question from the President's office: how can we help if we don't know what you are?
In Vivo - August 27, 2026